Latest advances in adult gastrointestinal stromal tumors

Vaia Florou, Breelyn A Wilky, Jonathan Trent

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common GI tract mesenchymal tumors. GIST patients are optimally managed by a precision medicine approach. Herein, we discuss the latest advances in precision medicine and ongoing clinical trials relevant to GIST. Circulating tumor DNA for detection of mutational changes could replace tissue biopsies and radiographic imaging once validated. Most GISTs are KIT/PDGFRα mutated, and despite the good clinical response to imatinib, treatment is generally not curative, more often due to secondary mutations. New mechanisms to bypass this resistance by inhibiting KIT downstream pathways and by targeting multiple KIT or PDGFRα mutations are being investigated. Immunotherapy for GIST patients is in its infancy. These approaches may lead to more effective, less toxic therapies.

Original languageEnglish (US)
Pages (from-to)2183-2193
Number of pages11
JournalFuture Oncology
Volume13
Issue number24
DOIs
StatePublished - Oct 1 2017

Fingerprint

Gastrointestinal Stromal Tumors
Precision Medicine
Mutation
Poisons
Immunotherapy
Gastrointestinal Tract
Neoplasms
Clinical Trials
Biopsy
DNA
Therapeutics

Keywords

  • circulating tumor DNA
  • GIST
  • KIT
  • PDGFRα
  • quadruple WT GIST

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Latest advances in adult gastrointestinal stromal tumors. / Florou, Vaia; Wilky, Breelyn A; Trent, Jonathan.

In: Future Oncology, Vol. 13, No. 24, 01.10.2017, p. 2183-2193.

Research output: Contribution to journalReview article

Florou, Vaia ; Wilky, Breelyn A ; Trent, Jonathan. / Latest advances in adult gastrointestinal stromal tumors. In: Future Oncology. 2017 ; Vol. 13, No. 24. pp. 2183-2193.
@article{ba6b5d7388b54286ab0190920ffa4f1c,
title = "Latest advances in adult gastrointestinal stromal tumors",
abstract = "Gastrointestinal stromal tumors (GISTs) are the most common GI tract mesenchymal tumors. GIST patients are optimally managed by a precision medicine approach. Herein, we discuss the latest advances in precision medicine and ongoing clinical trials relevant to GIST. Circulating tumor DNA for detection of mutational changes could replace tissue biopsies and radiographic imaging once validated. Most GISTs are KIT/PDGFRα mutated, and despite the good clinical response to imatinib, treatment is generally not curative, more often due to secondary mutations. New mechanisms to bypass this resistance by inhibiting KIT downstream pathways and by targeting multiple KIT or PDGFRα mutations are being investigated. Immunotherapy for GIST patients is in its infancy. These approaches may lead to more effective, less toxic therapies.",
keywords = "circulating tumor DNA, GIST, KIT, PDGFRα, quadruple WT GIST",
author = "Vaia Florou and Wilky, {Breelyn A} and Jonathan Trent",
year = "2017",
month = "10",
day = "1",
doi = "10.2217/fon-2017-0245",
language = "English (US)",
volume = "13",
pages = "2183--2193",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "24",

}

TY - JOUR

T1 - Latest advances in adult gastrointestinal stromal tumors

AU - Florou, Vaia

AU - Wilky, Breelyn A

AU - Trent, Jonathan

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Gastrointestinal stromal tumors (GISTs) are the most common GI tract mesenchymal tumors. GIST patients are optimally managed by a precision medicine approach. Herein, we discuss the latest advances in precision medicine and ongoing clinical trials relevant to GIST. Circulating tumor DNA for detection of mutational changes could replace tissue biopsies and radiographic imaging once validated. Most GISTs are KIT/PDGFRα mutated, and despite the good clinical response to imatinib, treatment is generally not curative, more often due to secondary mutations. New mechanisms to bypass this resistance by inhibiting KIT downstream pathways and by targeting multiple KIT or PDGFRα mutations are being investigated. Immunotherapy for GIST patients is in its infancy. These approaches may lead to more effective, less toxic therapies.

AB - Gastrointestinal stromal tumors (GISTs) are the most common GI tract mesenchymal tumors. GIST patients are optimally managed by a precision medicine approach. Herein, we discuss the latest advances in precision medicine and ongoing clinical trials relevant to GIST. Circulating tumor DNA for detection of mutational changes could replace tissue biopsies and radiographic imaging once validated. Most GISTs are KIT/PDGFRα mutated, and despite the good clinical response to imatinib, treatment is generally not curative, more often due to secondary mutations. New mechanisms to bypass this resistance by inhibiting KIT downstream pathways and by targeting multiple KIT or PDGFRα mutations are being investigated. Immunotherapy for GIST patients is in its infancy. These approaches may lead to more effective, less toxic therapies.

KW - circulating tumor DNA

KW - GIST

KW - KIT

KW - PDGFRα

KW - quadruple WT GIST

UR - http://www.scopus.com/inward/record.url?scp=85032623685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032623685&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0245

DO - 10.2217/fon-2017-0245

M3 - Review article

C2 - 28984483

AN - SCOPUS:85032623685

VL - 13

SP - 2183

EP - 2193

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 24

ER -